Elicio Therapeutics Inc. (ELTX) - Total Liabilities
Based on the latest financial reports, Elicio Therapeutics Inc. (ELTX) has total liabilities worth $24.13 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ELTX net asset momentum to track the company's year-over-year net asset growth rate.
Elicio Therapeutics Inc. - Total Liabilities Trend (2012–2025)
This chart illustrates how Elicio Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Elicio Therapeutics Inc. free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Elicio Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Elicio Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Veem Ltd
AU:VEE
|
Australia | AU$42.93 Million |
|
Brera Holdings PLC
NASDAQ:SLMT
|
USA | $22.25 Million |
|
Sleep Cycle AB
ST:SLEEP
|
Sweden | Skr128.31 Million |
|
Wahana Ottomitra Multiartha
JK:WOMF
|
Indonesia | Rp5.39 Trillion |
|
Cokal Ltd
AU:CKA
|
Australia | AU$64.22 Million |
|
Widodo Makmur Perkasa PT
JK:WMPP
|
Indonesia | Rp4.06 Trillion |
|
Charnic Capital Tbk PT
JK:NICK
|
Indonesia | Rp3.54 Billion |
|
SDS Group Bhd
KLSE:0212
|
Malaysia | RM73.84 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Elicio Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Elicio Therapeutics Inc. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -16.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Elicio Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Elicio Therapeutics Inc. (2012–2025)
The table below shows the annual total liabilities of Elicio Therapeutics Inc. from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $24.23 Million | -38.65% |
| 2024-12-31 | $39.49 Million | +150.36% |
| 2023-12-31 | $15.77 Million | +14.72% |
| 2022-12-31 | $13.75 Million | -8.38% |
| 2021-12-31 | $15.01 Million | -89.11% |
| 2020-12-31 | $137.80 Million | +352.21% |
| 2019-12-31 | $30.47 Million | +294.87% |
| 2018-12-31 | $7.72 Million | +16.87% |
| 2013-12-31 | $6.60 Million | -2.78% |
| 2012-12-31 | $6.79 Million | -- |
About Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targ… Read more